ADVANTAGE CHEMILUMINESCENCE PROSTATE SPECIFIC ANTIGEN (PSA) IMMUNOASSAY

Prostate-specific Antigen (psa) For Management Of Prostate Cancers

NICHOLS INSTITUTE DIAGNOSTICS

The following data is part of a premarket notification filed by Nichols Institute Diagnostics with the FDA for Advantage Chemiluminescence Prostate Specific Antigen (psa) Immunoassay.

Pre-market Notification Details

Device IDK980716
510k NumberK980716
Device Name:ADVANTAGE CHEMILUMINESCENCE PROSTATE SPECIFIC ANTIGEN (PSA) IMMUNOASSAY
ClassificationProstate-specific Antigen (psa) For Management Of Prostate Cancers
Applicant NICHOLS INSTITUTE DIAGNOSTICS 33051 CALLE AVIADOR San Juan Capistrano,  CA  92675
ContactDave Smith
CorrespondentDave Smith
NICHOLS INSTITUTE DIAGNOSTICS 33051 CALLE AVIADOR San Juan Capistrano,  CA  92675
Product CodeLTJ  
CFR Regulation Number866.6010 [🔎]
DecisionSubstantially Equivalent (SESE)
TypeTraditional
3rd Party ReviewedNo
Combination ProductNo
Date Received1998-01-07
Decision Date1998-04-03
Summary:summary

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.